In this review, we reported the current evidence about two unmet needs in advanced melanoma: the optimal treatment duration of the anti-PD1-based regimens for responding patients and the durability of the response in terms of survival for patients discontinuing the therapy due to irAEs. The gene discussed is PDCD1; the disease is melanoma.